Published: 2 July 2021
Author(s): Andrea Ricci, Matteo Marcacci, Chiara Cuoghi, Antonello Pietrangelo, Paolo Ventura
Issue: October 2021
Section: Letter to the Editor

Acute hepatic porphyrias (AHPs) are a group of rare diseases caused by an enzymatic dysfunction in the biosynthesis of heme [1]. AHPs’ clinical landmarks are recurrent crisis of neurovisceral attacks [acute porphyric attacks (APAs)], characterized by severe abdominal pain and peripheral and central neurological involvement, ranging from mild-moderate to life-threatening. APAs are usually unleashed by trigger events (e.g. fasting, alcohol intake, menses, use of ”porphyrinogenic” drugs or hormones) responsible for a supposed further relative heme deficiency, in turn inducing an up-regulation of liver δ-amino-levulinic acid synthase (ALAS1), the first enzyme of the pathway leading to heme biosynthesis.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.